ArticleBMC oral health2026
Elevated expression of JAK1 and pJAK1 in oral lichen planus: a retrospective study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Melissa officinalis extract selectively suppresses STAT1 signaling in oral epithelial cells.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJanus kinase (JAK) inhibitors have recently emerged as potential therapeutic agents for oral lichen planus (OLP). In OLP, cytokine-mediated immune activation is thought to involve the JAK/STAT signaling pathway; however, the precise role of this pathway remains incompletely understood. Therefore, this study aimed to investigate the expression of JAK1 and its activated form, pJAK1, in OLP.
methodsIn this retrospective study, forty-four formalin-fixed, paraffin-embedded OLP and nineteen normal oral mucosa (NOM) specimens were analyzed using immunohistochemistry to assess JAK1 and pJAK1 expression. The number of JAK1 and pJAK1 positive cells in the epithelium and inflammatory infiltrate, as well as the total number of epithelial and inflammatory cells, were counted. The percentage of JAK1 and pJAK1 expression in OLP and NOM was then compared.
resultsJAK1 and pJAK1 expression was significantly increased in both epithelial cells (p = 0.007 and p = 0.001, respectively) and infiltrating inflammatory cells (p < 0.001 and p = 0.017, respectively) in OLP compared with NOM. In epithelial cells, the median percentages of JAK1 and pJAK1 positive cells in OLP were 63.62 (42.77, 96.01) and 55.68 (44.72, 59.22), respectively, compared with 32.51 (10.77, 89.95) and 24.25 (12.54, 66.20) in NOM. Similarly, median JAK1 and pJAK1 expression in infiltrating inflammatory cells was higher in OLP (65.40 (40.45, 81.31) and 44.18 (19.40, 66.96), respectively) than in NOM (14.71 (7.69, 66.91) and 14.54 (8.88, 28.37)).
conclusionsThe significant overexpression of JAK1 and pJAK1 in OLP suggests an involvement in its pathogenesis. However, given the retrospective design, further prospective studies and functional analyses are necessary to confirm these findings and to explore the potential role of JAK inhibitors in the management of OLP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.